David Neff
Research Subjects
David Neff has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Changgeng Zhao
Merck, Sharp & Dohme Corp, Whitehouse Station, New Jersey
3 shared publicationsNing Jackie Zhang
University of Central Florida, Orlando, Florida
3 shared publications- Andrew M. Tershakovec
Merck & Co., Inc., Cardiovascular, Kenilworth, USA
2 shared publications Andrew Tershakovec
Merck & Co, Inc., Whitehouse Station, NJ, USA
2 shared publicationsDena Ramey
Merck & Co, Inc., Whitehouse Station, NJ, USA
2 shared publicationsElizabeth Marrett
Merck, Sharp & Dohme Corp, Whitehouse Station, New Jersey
2 shared publications
Latest Publications
- 1 May 2014
- Published by Elsevier in Clinical Therapeutics
- Vol. 36 (5) , 792-799
LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy
- 1 May 2014
- Published by Elsevier in Clinical Therapeutics
- Vol. 36 (5) , 792-799
LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy
- Open Access
- 1 April 2014
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 10, 237-46
Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US
Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes. Atorvastatin is a common statin with greater LDL-C lowering efficacy than most other statins; its availability in generic form will likely increase its use. This study assessed attainment of guideline-recommended LDL-C levels in high-risk CVD patients treated with atorvastatin monotherapy. Analyses of two retrospective US cohorts of patients who received a prescription for atorvastatin monotherapy between January 1, 2008 and December 31, 2010 (index date defined as first prescription date) in the GE Centricity Electronic Medical Record (EMR) (N=10,693) and Humana Medicare (N=16,798) databases. Eligible patients were ≥18 years, diagnosed with coronary heart disease or atherosclerotic vascular disease, with ≥1 LDL-C measurement between 3 months and 1 year postindex date, and continuously enrolled for 1 year prior to and following the index date. Of the eligible patients, 21.8%, 29.6%, 29.9%, and 18.7% (GE Centricity EMR) and 25.4%, 32.9%, 27.8%, and 14.0% (Humana Medicare) received 10, 20, 40, and 80 mg doses of atorvastatin, respectively. The mean ± standard deviation (SD) follow-up LDL-C levels were 2.1±0.8 mmol/L (83±30 mg/dL) and 2.3±0.8 mmol/L (88±31 mg/dL) for the GE Centricity EMR and Humana Medicare cohorts, respectively. Regardless of dose, only 28.3%-34.8% of patients had LDL-C levels 1.8 mmol/L (>70 mg/dL), and of these, 30%-40% had LDL-C levels ≥0.5 mmol/L (≥20 mg/dL) above this, regardless of dose. This suggests that more effective lipid-lowering strategies, such as statin uptitration, switching to a higher efficacy statin, and/or combination therapy, may be required to achieve optimal LDL-C lowering in high-risk patients.
- 1 April 2014
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 10, 237-46
Open AccessLimitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US
Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes. Atorvastatin is a common statin with greater LDL-C lowering efficacy than most other statins; its availability in generic form will likely increase its use. This study assessed attainment of guideline-recommended LDL-C levels in high-risk CVD patients treated with atorvastatin monotherapy. Analyses of two retrospective US cohorts of patients who received a prescription for atorvastatin monotherapy between January 1, 2008 and December 31, 2010 (index date defined as first prescription date) in the GE Centricity Electronic Medical Record (EMR) (N=10,693) and Humana Medicare (N=16,798) databases. Eligible patients were ≥18 years, diagnosed with coronary heart disease or atherosclerotic vascular disease, with ≥1 LDL-C measurement between 3 months and 1 year postindex date, and continuously enrolled for 1 year prior to and following the index date. Of the eligible patients, 21.8%, 29.6%, 29.9%, and 18.7% (GE Centricity EMR) and 25.4%, 32.9%, 27.8%, and 14.0% (Humana Medicare) received 10, 20, 40, and 80 mg doses of atorvastatin, respectively. The mean ± standard deviation (SD) follow-up LDL-C levels were 2.1±0.8 mmol/L (83±30 mg/dL) and 2.3±0.8 mmol/L (88±31 mg/dL) for the GE Centricity EMR and Humana Medicare cohorts, respectively. Regardless of dose, only 28.3%-34.8% of patients had LDL-C levels 1.8 mmol/L (>70 mg/dL), and of these, 30%-40% had LDL-C levels ≥0.5 mmol/L (≥20 mg/dL) above this, regardless of dose. This suggests that more effective lipid-lowering strategies, such as statin uptitration, switching to a higher efficacy statin, and/or combination therapy, may be required to achieve optimal LDL-C lowering in high-risk patients.
- 1 May 2013
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 7 (3) , 247-248
Suboptimal LDL-C Lowering in High-risk Patients with Coronary Heart Disease or Atherosclerotic Vascular Disease in the U.S.
- 1 May 2013
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 7 (3) , 247-248
Suboptimal LDL-C Lowering in High-risk Patients with Coronary Heart Disease or Atherosclerotic Vascular Disease in the U.S.
- 1 May 2012
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 6 (3) , 254-255
Changes in Lipoprotein Particle Number with Ezetimibe/Simvastatin Co-administered with Extended-Release Niacin in Patients with Type II Hyperlipidemia†
- 1 May 2012
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 6 (3) , 254-255
Changes in Lipoprotein Particle Number with Ezetimibe/Simvastatin Co-administered with Extended-Release Niacin in Patients with Type II Hyperlipidemia†
- 1 May 2012
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 6 (3) , 253-254
Changes in Lipoprotein-associated Phospholipase A2 with Ezetimibe/Simvastatin Co-administered with ER Niacin in Type II Hyperlipidemia
- 1 May 2012
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 6 (3) , 253-254
Changes in Lipoprotein-associated Phospholipase A2 with Ezetimibe/Simvastatin Co-administered with ER Niacin in Type II Hyperlipidemia